Leukotriene synthesis inhibitors

A compound of formula (1)

• or a pharmaceutically acceptable enantiomer, diastereomer, salt, or solvate thereof, wherein:
• Ar is a 9- or 10-membered bicyclic aromatic ring system, where Ar is substituted with one, two or three substituents, wherein Ar is substituted with at least one —S—CH3;
• L is selected from a direct bond and methylene;
• R1 is selected from hydrogen, halide, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy, C3-C6cycloalkoxy and C1-C6alkoxy substituted with C3-C6cycloalkyl;
• A is selected from a direct bond, —CH2— and —CH2CH2—;
• E is C(OR3)R4R5;
• R3 is selected from H, alkyl and substituted alkyl;
• R4 is selected from hydrogen, alkyl and phenyl;
• and
• R5 is selected from C1-C7alkyl, C1-C7haloalkyl, phenyl and substituted phenyl.